author-photo

Byung Ha Chung

Yonsei University
University Health System

506

Papers

4655

Citations

Citation Trend

Filter By

Papers (373) Sort By

Journal Conference Others

Effect of training and individual operator's expertise on prostate cancer detection through prostate biopsy: Implications for the current quantitative training evaluation system

2021 Investigative and Clinical Urology
Show All
- Source
- Cite
- Save
Citations (0)
Intrapatient Variability in Tacrolimus Trough Levels Over 2 Years Affects Long-Term Allograft Outcomes of Kidney Transplantation

2021 Frontiers in Immunology
Show All
- Source
- Cite
- Save
Citations (0)
Pain control according to the periprostatic nerve block site in magnetic resonance imaging/transrectal targeted prostate biopsy

2021
Show All
- Source
- Cite
- Save
Citations (0)
608P Apalutamide (APA) efficacy and safety in Asian patients with metastatic castration-sensitive prostate cancer (mCSPC)

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Tacrolimus Decreases Cognitive Function by Impairing Hippocampal Synaptic Balance: A Possible Role of Klotho

2021
Show All
- Source
- Cite
- Save
Citations (0)
Comparison of CT Volumetry versus Nuclear Renography for Predicting Remaining Kidney Function After Uninephrectomy in Living Kidney Donors

2021
Show All
- Source
- Cite
- Save
Citations (0)
Usefulness of Prostate-Specific Antigen Density as an Indicator for Recommending Prebiopsy Magnetic Resonance Imaging to Prevent Missed Prostate Cancer Diagnoses

2021
Show All
- Source
- Cite
- Save
Citations (0)
Apalutamide Plus Androgen Deprivation Therapy for Metastatic Castration-Sensitive Prostate Cancer: Analysis of Pain and Fatigue in the Phase 3 TITAN Study.

2021 The Journal of Urology
Show All
- Source
- Cite
- Save
Citations (0)
Health-related quality of life (HRQoL) and patient-reported outcomes at final analysis of the TITAN study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Final analysis results from TITAN: A phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (2)